October 23, 2020:
In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights a variety of activities and accomplishments across Big Ten universities. Highlights include new leadership announcements, grant awards, study publications, and novel treatments to continue the fight against cancer. Read More
October 1, 2020: Excerpt reposted with permission from the Erie Times-News. The Big Ten is best known for football. But in 2013, member universities teamed to collaborate rather than compete, in cancer research. The Big Ten Cancer Research Consortium, based at the Hoosier Cancer Research Network in Indianapolis, Ind., helps researchers at 15 universities work together to fight cancer. The consortium includes the Penn State Cancer Institute, Rutgers University Cancer Institute of New Jersey, and the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. “The idea was to get all those football colleges and cancer institutes together to build a forum so that people from member institutions can conduct collaborative research and clinical trials,” said Monika Joshi, MD, who represents the...
October 9, 2020: A Big Ten Cancer Research Consortium phase II study for adult patients with advanced salivary gland carcinoma that is androgen receptor positive (AR+), will test the combined therapy of the PD-1 inhibitor pembrolizumab and the androgen deprivation therapy goserelin. This multi-site study is now open to accrual at the University of Illinois Cancer Center (University of Illinois at Chicago); Holden Comprehensive Cancer Center, University of Iowa; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center; Read More
October 9, 2020: Big Ten Cancer Research Consortium investigators recently presented an E-Poster on the BTCRC-GU16-043 study during the ESMO 2020 Virtual Congress. The clinical trial is investigating whether adding guadecitabine, a drug that targets DNA methylation, might increase the proportion of patients with advanced clear cell renal cell carcinoma (ccRCC) who respond to treatment with durvalumab, a checkpoint-inhibitor drug that targets the PD-1/PD-L1 pathway. “In the past decade, checkpoint inhibitors have been a valuable addition to the therapeutic armamentarium of kidney cancer. However, not all patients benefit from this therapy, and there is an unmet need to further improve the clinical outcomes with novel combination...
October 1, 2020: Applications are now open for a nationwide integrative oncology training program. The Integrative Oncology Scholars Program at the University of Michigan is funded by a National Cancer Institute R25 grant. It has the joint goals of training 100 integrative oncology (IO) leaders over 4 years and facilitating partnerships between IO leaders and complementary practitioners within their communities. Read More
September 29, 2020: A phase Ib Big Ten Cancer Research Consortium multi-center study is testing the safety and efficacy of the monoclonal antibody gemtuzumab ozogamicin when combined with the BCL-2 inhibitor venetoclax in adults with relapsed or refractory acute myeloid leukemia. The study is open to accrual at the University of Illinois Cancer Center in Chicago, Ill.; the Indiana University Melvin and Bren Simon Comprehensive Cancer Center in Indianapolis, Ind.; the University of Michigan Rogel Cancer Center in Ann Arbor, Mich.; and the
September 25, 2020: Researchers at Penn State University are leading a multi-center phase II Big Ten Cancer Research Consortium study for adults with previously untreated, locally advanced pancreatic cancer that tests liposomal irinotecan in combination with FOLFOX, a chemotherapy regimen that includes oxaliplatin, leucovorin, and 5-fluorouracil. Researchers hope to determine the disease control rate of this combination — the percentage of patients whose tumors respond to treatment or remain stable. The study could help determine if this novel approach could be used as a first-line treatment for locally advanced pancreatic cancer. Liposomal irinotecan uses a tiny bubble called a liposome that is made of the same material as a cell wall. The liposome is filled with a drug called irinotecan that will circulate through a...
September 24, 2020: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights a variety of activities and accomplishments across universities. From new cancer drugs, to grant awards and new methods of treatments, researchers stop at nothing to continue to fight against cancer. Read More
September 9, 2020: This month, the Big Ten Cancer Research Consortium highlights the University of Wisconsin Carbone Cancer Center as our featured member. UW Carbone member Elisavet Paplomata, MD, an assistant professor in the Department of Medicine, shares her research interests and expertise in breast and gynecologic cancers in this story, originally published by uwhealth.org.
August 19, 2020: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights investigators focusing on breast cancer research and recent grants awarded to researchers and cancer centers across the Big Ten CRC. Read More
University of Illinois
Indiana University
University of Iowa
University of Maryland
University of Michigan
Michigan State
University of Minnesota
University of Nebraska
Northwestern University
Penn State University
Purdue University
Rutgers State University
University of Wisconsin
University of Illinois at Chicago
© 2024 All rights reserved.
Big Ten Cancer Research Consortium
7676 Interactive Way, Suite 120, Indianapolis, IN 46278
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube